About Cytosorbents (NASDAQ:CTSO)
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Trailing P/E Ratio-35.63
Forward P/E Ratio-24.78
Sales & Book Value
Annual Sales$15.15 million
Price / Sales22.60
Price / CashN/A
Book Value$0.36 per share
Price / Book31.67
EPS (Most Recent Fiscal Year)($0.32)
Return on Equity-88.39%
Return on Assets-38.47%
Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions
What is Cytosorbents' stock symbol?
Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."
How were Cytosorbents' earnings last quarter?
Cytosorbents Corp (NASDAQ:CTSO) announced its earnings results on Tuesday, May, 8th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. The medical research company earned $4.93 million during the quarter, compared to analyst estimates of $4.56 million. Cytosorbents had a negative return on equity of 88.39% and a negative net margin of 56.06%. View Cytosorbents' Earnings History.
When is Cytosorbents' next earnings date?
What price target have analysts set for CTSO?
5 equities research analysts have issued twelve-month target prices for Cytosorbents' stock. Their forecasts range from $9.00 to $14.00. On average, they anticipate Cytosorbents' share price to reach $11.25 in the next twelve months. View Analyst Ratings for Cytosorbents.
Who are some of Cytosorbents' key competitors?
Some companies that are related to Cytosorbents include Luminex (LMNX), Orthofix International (OFIX), OraSure Technologies (OSUR), Intersect ENT (XENT), Atrion (ATRI), Cryolife (CRY), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD), Tandem Diabetes Care (TNDM), K2M Group (KTWO), AtriCure (ATRC), Cerus (CERS), AngioDynamics (ANGO), SurModics (SRDX) and LeMaitre Vascular (LMAT).
Who are Cytosorbents' key executives?
Cytosorbents' management team includes the folowing people:
- Dr. Phillip P. Chan M.D., Ph.D., CEO, Pres & Director (Age 48)
- Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 63)
- Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 60)
- Dr. Robert H. Bartlett M.D., Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 79)
- Dr. Christian Steiner M.D., VP of Sales & Marketing
Has Cytosorbents been receiving favorable news coverage?
Media coverage about CTSO stock has trended somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytosorbents earned a news sentiment score of 0.05 on Accern's scale. They also assigned news stories about the medical research company an impact score of 47.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Cytosorbents' major shareholders?
Cytosorbents' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.28%), Granite Investment Partners LLC (0.20%), Tibra Equities Europe Ltd (0.17%) and Element Capital Management LLC (0.10%). Company insiders that own Cytosorbents stock include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents.
Which institutional investors are buying Cytosorbents stock?
CTSO stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Granite Investment Partners LLC, Tibra Equities Europe Ltd and Element Capital Management LLC. Company insiders that have bought Cytosorbents stock in the last two years include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents.
How do I buy shares of Cytosorbents?
Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytosorbents' stock price today?
One share of CTSO stock can currently be purchased for approximately $11.40.
How big of a company is Cytosorbents?
Cytosorbents has a market capitalization of $370.89 million and generates $15.15 million in revenue each year. The medical research company earns $-8,460,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Cytosorbents employs 84 workers across the globe.
How can I contact Cytosorbents?
Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]
MarketBeat Community Rating for Cytosorbents (CTSO)MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.